Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Debt: 2024-2025

Historic Non-Current Debt for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $5.3 million.

  • Kura Oncology's Non-Current Debt fell 31.21% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 31.21%. This contributed to the annual value of $6.9 million for FY2024, which is N/A change from last year.
  • Kura Oncology's Non-Current Debt amounted to $5.3 million in Q3 2025, which was down 18.02% from $6.5 million recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's Non-Current Debt peaked at $9.4 million during Q1 2024, and registered a low of $5.3 million during Q3 2025.
  • Moreover, its 2-year median value for Non-Current Debt was $7.7 million (2025), whereas its average is $7.4 million.
  • Data for Kura Oncology's Non-Current Debt shows a maximum YoY crashed of 31.21% (in 2025) over the last 5 years.
  • Over the past 2 years, Kura Oncology's Non-Current Debt (Quarterly) stood at $6.9 million in 2024, then slumped by 31.21% to $5.3 million in 2025.
  • Its Non-Current Debt stands at $5.3 million for Q3 2025, versus $6.5 million for Q2 2025 and $7.7 million for Q1 2025.